

Adam Bagg

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3194611/publications.pdf>

Version: 2024-02-01

185
papers

12,918
citations

159585

30
h-index

23533

111
g-index

187
all docs

187
docs citations

187
times ranked

13629
citing authors

#	ARTICLE	IF	CITATIONS
1	Chimeric Antigen Receptorâ€“Modified T Cells in Chronic Lymphoid Leukemia. <i>New England Journal of Medicine</i> , 2011, 365, 725-733.	27.0	3,067
2	T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia. <i>Science Translational Medicine</i> , 2011, 3, 95ra73.	12.4	2,006
3	Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. <i>Science Translational Medicine</i> , 2015, 7, 303ra139.	12.4	1,402
4	Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. <i>Molecular Genetics and Metabolism</i> , 2003, 80, 148-158.	1.1	1,309
5	Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma. <i>New England Journal of Medicine</i> , 2015, 373, 1040-1047.	27.0	511
6	Survival of acute myeloid leukemia cells requires PI3 kinase activation. <i>Blood</i> , 2003, 102, 972-980.	1.4	432
7	Utility of FDG-PET scanning in lymphoma by WHO classification. <i>Blood</i> , 2003, 101, 3875-3876.	1.4	415
8	International, evidence-based consensus diagnostic criteria for HHV-8â€“negative/idiopathic multicentric Castleman disease. <i>Blood</i> , 2017, 129, 1646-1657.	1.4	381
9	Bone marrow fibrosis: pathophysiology and clinical significance of increased bone marrow stromal fibres. <i>British Journal of Haematology</i> , 2007, 139, 351-362.	2.5	249
10	Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms. <i>Blood</i> , 2014, 123, 2645-2651.	1.4	192
11	In situ mantle cell lymphoma: clinical implications of an incidental finding with indolent clinical behavior. <i>Haematologica</i> , 2012, 97, 270-278.	3.5	146
12	Erythropoietin gene therapy leads to autoimmune anemia in macaques. <i>Blood</i> , 2004, 103, 3300-3302.	1.4	141
13	Guidance for Fluorescence in Situ Hybridization Testing in Hematologic Disorders. <i>Journal of Molecular Diagnostics</i> , 2007, 9, 134-143.	2.8	121
14	Targeted next-generation sequencing identifies a subset of idiopathic hypereosinophilic syndrome with features similar to chronic eosinophilic leukemia, not otherwise specified. <i>Modern Pathology</i> , 2016, 29, 854-864.	5.5	104
15	A Phase I Study of the Mammalian Target of Rapamycin Inhibitor Sirolimus and MEC Chemotherapy in Relapsed and Refractory Acute Myelogenous Leukemia. <i>Clinical Cancer Research</i> , 2009, 15, 6732-6739.	7.0	97
16	Immunoglobulin Heavy Chain Gene Analysis in Lymphomas. <i>Journal of Molecular Diagnostics</i> , 2002, 4, 81-89.	2.8	95
17	Preexisting Immunity to Adenovirus in Rhesus Monkeys Fails To Prevent Vector-Induced Toxicity. <i>Journal of Virology</i> , 2002, 76, 5711-5719.	3.4	80
18	Bone marrow morphology is a strong discriminator between chronic eosinophilic leukemia, not otherwise specified and reactive idiopathic hypereosinophilic syndrome. <i>Haematologica</i> , 2017, 102, 1352-1360.	3.5	62

#	ARTICLE	IF	CITATIONS
19	Identification of the chimeric protein product of the <i>CBF&MYH11</i> fusion gene in <i>inv(16)</i> leukemia cells. <i>Genes Chromosomes and Cancer</i> , 1996, 16, 77-87.	2.8	61
20	Complex or monosomal karyotype and not blast percentage is associated with poor survival in acute myeloid leukemia and myelodysplastic syndrome patients with <i>inv(3)(q21q26.2)/t(3;3)(q21;q26.2)</i> : a Bone Marrow Pathology Group study. <i>Haematologica</i> , 2014, 99, 821-829.	3.5	61
21	Coexisting Follicular and Mantle Cell Lymphoma With Each Having an In Situ Component. <i>American Journal of Clinical Pathology</i> , 2010, 133, 584-591.	0.7	58
22	Chronic myelogenous leukemia: Laboratory diagnosis and monitoring. <i>Genes Chromosomes and Cancer</i> , 2001, 32, 97-111.	2.8	53
23	Oligomonocytic chronic myelomonocytic leukemia (chronic myelomonocytic leukemia without) <i>Tj ETQq1 1 0.784314 rgBT /Overlock</i> chronic myelomonocytic leukemia. <i>Modern Pathology</i> , 2017, 30, 1213-1222.	5.5	52
24	Hematopoietic neoplasms with <i>9p24/JAK2</i> rearrangement: a multicenter study. <i>Modern Pathology</i> , 2019, 32, 490-498.	5.5	50
25	Clinicopathologic and genetic characterization of nonacute <i>NPM1</i> -mutated myeloid neoplasms. <i>Blood Advances</i> , 2019, 3, 1540-1545.	5.2	44
26	Evaluation of T Cell Receptor Testing in Lymphoid Neoplasms. <i>Journal of Molecular Diagnostics</i> , 2001, 3, 133-140.	2.8	39
27	Multiplex RT-PCR for the Detection of Leukemia-Associated Translocations. <i>Journal of Molecular Diagnostics</i> , 2003, 5, 231-236.	2.8	37
28	Myeloproliferative neoplasms with concurrent <i>BCR&ABL1</i> translocation and <i>JAK2 V617F</i> mutation: a multi-institutional study from the bone marrow pathology group. <i>Modern Pathology</i> , 2018, 31, 690-704.	5.5	35
29	Immunosuppressive and immunomodulatory therapy-associated lymphoproliferative disorders. <i>Seminars in Diagnostic Pathology</i> , 2013, 30, 102-112.	1.5	34
30	<i>CD79a</i> Is Heterogeneously Expressed in Neoplastic and Normal Myeloid Precursors and Megakaryocytes in an Antibody Clone"Dependent Manner. <i>American Journal of Clinical Pathology</i> , 2007, 128, 306-313.	0.7	32
31	A Phase I Study of Bexarotene, a Retinoic X Receptor Agonist, in Non-M3 Acute Myeloid Leukemia. <i>Clinical Cancer Research</i> , 2008, 14, 5619-5625.	7.0	32
32	The Genetic Basis and Expanding Role of Molecular Analysis in the Diagnosis, Prognosis, and Therapeutic Design for Myelodysplastic Syndromes. <i>Journal of Molecular Diagnostics</i> , 2014, 16, 145-158.	2.8	32
33	Cyclin D1 expression and novel mutational findings in <i>Rosai&Dorfman</i> disease. <i>British Journal of Haematology</i> , 2019, 186, 837-844.	2.5	31
34	Molecular diagnosis and monitoring in the clinical management of patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors. <i>American Journal of Hematology</i> , 2008, 83, 296-302.	4.1	30
35	Automated screening for myelodysplastic syndromes through analysis of complete blood count and cell population data parameters. <i>American Journal of Hematology</i> , 2014, 89, 369-374.	4.1	30
36	Recurrence of Nodal Diffuse Large B-Cell Lymphoma as Intravascular Large B-Cell Lymphoma: Is an Intravascular Component at Initial Diagnosis Predictive?. <i>Archives of Pathology and Laboratory Medicine</i> , 2005, 129, 391-394.	2.5	29

#	ARTICLE	IF	CITATIONS
37	A Comparative Analysis of Molecular Genetic and Conventional Cytogenetic Detection of Diagnostically Important Translocations in More Than 400 Cases of Acute Leukemia, Highlighting the Frequency of False-Negative Conventional Cytogenetics. <i>American Journal of Clinical Pathology</i> , 2011, 135, 921-928.	0.7	28
38	Unusually indolent T-cell prolymphocytic leukemia associated with a complex karyotype: Is this T-cell chronic lymphocytic leukemia?. <i>American Journal of Hematology</i> , 2002, 71, 224-226.	4.1	27
39	Genetic aberrations in small B-cell lymphomas and leukemias: molecular pathology, clinical relevance and therapeutic targets. <i>Leukemia and Lymphoma</i> , 2016, 57, 1991-2013.	1.3	26
40	Role of high-throughput sequencing in the diagnosis of cutaneous T-cell lymphoma. <i>Journal of Clinical Pathology</i> , 2018, 71, 814-820.	2.0	26
41	Comparison of therapy-related and de novo core binding factor acute myeloid leukemia: A bone marrow pathology group study. <i>American Journal of Hematology</i> , 2020, 95, 799-808.	4.1	26
42	Chronic Myeloid Leukemia. <i>Journal of Molecular Diagnostics</i> , 2002, 4, 1-10.	2.8	25
43	CD5-Negative, CD10-Negative small B-cell leukemia: Variant of chronic lymphocytic leukemia or a distinct entity?. <i>American Journal of Hematology</i> , 2002, 71, 306-310.	4.1	25
44	FLT3Inhibitor-Associated Neutrophilic Dermatoses. <i>JAMA Dermatology</i> , 2016, 152, 480.	4.1	25
45	Clinical, immunophenotypic, and genomic findings of acute undifferentiated leukemia and comparison to acute myeloid leukemia with minimal differentiation: a study from the bone marrow pathology group. <i>Modern Pathology</i> , 2019, 32, 1373-1385.	5.5	25
46	Posttherapy Surveillance of B-Cell Precursor Acute Lymphoblastic Leukemia: Value of Polymerase Chain Reaction and Limitations of Flow Cytometry. <i>American Journal of Clinical Pathology</i> , 1999, 111, 759-766.	0.7	23
47	Aggressive Epstein-Barr Virus-Associated, CD8+, CD30+, CD56+, Surface CD3 ⁺ , Natural Killer (NK)-Like Cytotoxic T-Cell Lymphoma. <i>American Journal of Surgical Pathology</i> , 2002, 26, 111-118.	3.7	23
48	Expanded Populations of Surface Membrane Immunoglobulin Light Chain ⁻ Negative B Cells in Lymph Nodes Are Not Always Indicative of B-Cell Lymphoma. <i>American Journal of Clinical Pathology</i> , 2005, 124, 143-150.	0.7	23
49	T-Cell Large Granular Lymphocytic Leukemia and Coexisting B-Cell Lymphomas. <i>American Journal of Clinical Pathology</i> , 2018, 149, 164-171.	0.7	23
50	Flow-cytometric analysis of peripheral blood neutrophils: A simple, objective, independent and potentially clinically useful assay to facilitate the diagnosis of myelodysplastic syndromes. <i>American Journal of Hematology</i> , 2005, 79, 243-245.	4.1	22
51	De novo acute myeloid leukemia with 20-29% blasts is less aggressive than acute myeloid leukemia with ≥30% blasts in older adults: a Bone Marrow Pathology Group study. <i>American Journal of Hematology</i> , 2014, 89, E193-9.	4.1	22
52	JAK2 ^{V617F} -positive acute myeloid leukaemia (AML): a comparison between de novo AML and secondary AML transformed from an underlying myeloproliferative neoplasm. A study from the Bone Marrow Pathology Group. <i>British Journal of Haematology</i> , 2018, 182, 78-85.	2.5	22
53	The Routine Diagnostic Utility of Immunoglobulin and T-Cell Receptor Gene Rearrangements in Lymphoproliferative Disorders. <i>American Journal of Clinical Pathology</i> , 1989, 91, 633-638.	0.7	21
54	Temporal association of marrow eosinophilia with inversion of chromosome 16 in recurrent blast crises of chronic myelogenous leukemia. <i>Cancer Genetics and Cytogenetics</i> , 1992, 62, 134-139.	1.0	21

#	ARTICLE	IF	CITATIONS
55	Immunoglobulin and T-Cell Receptor Gene Rearrangements: Minding Your B's and T's in Assessing Lineage and Clonality in Neoplastic Lymphoproliferative Disorders. <i>Journal of Molecular Diagnostics</i> , 2006, 8, 426-429.	2.8	21
56	A novel t(3;8)(q27;q24.1) simultaneously involving both the BCL6 and MYC genes in a diffuse large B-cell lymphoma. <i>Cancer Genetics and Cytogenetics</i> , 2007, 172, 45-53.	1.0	21
57	Nucleophosmin (NPM1) Mutations in Acute Myeloid Leukemia: An Ongoing (Cytoplasmic) Tale of Dueling Mutations and Duality of Molecular Genetic Testing Methodologies. <i>Journal of Molecular Diagnostics</i> , 2008, 10, 198-202.	2.8	21
58	Molecular genetic characterization of lymphoma: Application to cytology diagnosis. <i>Diagnostic Cytopathology</i> , 2012, 40, 542-555.	1.0	21
59	Hodgkin Lymphoma. <i>Advances in Anatomic Pathology</i> , 2014, 21, 12-25.	4.3	21
60	NPM1 mutation is associated with leukemia cutis in acute myeloid leukemia with monocytic features. <i>Haematologica</i> , 2015, 100, e412-e414.	3.5	21
61	Concordance among hematopathologists in classifying blasts plus promonocytes: A bone marrow pathology group study. <i>International Journal of Laboratory Hematology</i> , 2020, 42, 418-422.	1.3	21
62	Myeloid/lymphoid neoplasms with FLT3 rearrangement. <i>Modern Pathology</i> , 2021, 34, 1673-1685.	5.5	21
63	Intravascular Large B-Cell Lymphoma: A Mimicker of Many Maladies and a Difficult and Often Delayed Diagnosis. <i>Journal of Clinical Oncology</i> , 2011, 29, e138-e140.	1.6	20
64	Clonal Replacement Underlies Spontaneous Remission in Paroxysmal Nocturnal Haemoglobinuria. <i>British Journal of Haematology</i> , 2017, 176, 487-490.	2.5	20
65	Sudden Extramedullary T-Lymphoblastic Blast Crisis in Chronic Myelogenous Leukemia. <i>American Journal of Clinical Pathology</i> , 2008, 129, 639-648.	0.7	19
66	Evaluation of Scopio Labs X100 Full Field PBS: The first high-resolution full field viewing of peripheral blood specimens combined with artificial intelligence-based morphological analysis. <i>International Journal of Laboratory Hematology</i> , 2021, 43, 1408-1416.	1.3	19
67	Multiple cutaneous monoclonal B-cell proliferations as harbingers of systemic angioimmunoblastic T-cell lymphoma. <i>Journal of Cutaneous Pathology</i> , 2010, 37, 777-786.	1.3	18
68	Î±-Hemoglobin-stabilizing Protein Is a Sensitive and Specific Marker of Erythroid Precursors. <i>American Journal of Surgical Pathology</i> , 2012, 36, 1538-1547.	3.7	18
69	Insufficient evidence exists to use histopathologic subtype to guide treatment of idiopathic multicentric Castleman disease. <i>American Journal of Hematology</i> , 2020, 95, 1553-1561.	4.1	18
70	Bone Marrow Reticulin in Patients with Immune Thrombocytopenic Purpura.. <i>Blood</i> , 2006, 108, 3982-3982.	1.4	18
71	Precursor T-cell lymphoma associated with human immunodeficiency virus type 1 (HIV-1) infection. First reported case. <i>Cancer</i> , 1989, 64, 39-42.	4.1	17
72	SHP-1 Expression by Malignant Small B-Cell Lymphomas Reflects the Maturation Stage of Their Normal B-Cell Counterparts. <i>American Journal of Surgical Pathology</i> , 2001, 25, 949-955.	3.7	17

#	ARTICLE	IF	CITATIONS
73	Primary cardiac lymphoma: Utility of multimodality imaging in diagnosis and management. <i>Cancer Biology and Therapy</i> , 2007, 6, 1867-1870.	3.4	17
74	Rosai-Dorfman Disease of the Breast With Variable IgG4+ Plasma Cells. <i>American Journal of Surgical Pathology</i> , 2019, 43, 1653-1660.	3.7	17
75	Germline POT1 variants can predispose to myeloid and lymphoid neoplasms. <i>Leukemia</i> , 2022, 36, 283-287.	7.2	17
76	Molecular diagnosis of acute myeloid leukemia. <i>Expert Review of Molecular Diagnostics</i> , 2010, 10, 993-1012.	3.1	15
77	Circulating monoclonal B-cells in multiple myeloma: association with lambda paraproteins. <i>British Journal of Haematology</i> , 1989, 72, 167-172.	2.5	14
78	Role of molecular studies in the classification of lymphoma. <i>Expert Review of Molecular Diagnostics</i> , 2004, 4, 83-97.	3.1	14
79	The Evolution of Molecular Genetic Pathology. <i>Journal of Molecular Diagnostics</i> , 2008, 10, 480-483.	2.8	14
80	Acute Myeloid Leukemia: Conventional Cytogenetics, FISH, and Moleculocentric Methodologies. <i>Clinics in Laboratory Medicine</i> , 2011, 31, 659-686.	1.4	14
81	Coactivation of NF- κ B and Notch signaling is sufficient to induce B-cell transformation and enables B-myeloid conversion. <i>Blood</i> , 2020, 135, 108-120.	1.4	14
82	Malleable Immunoglobulin Genes and Hematopathology – The Good, the Bad, and the Ugly. <i>Journal of Molecular Diagnostics</i> , 2008, 10, 396-410.	2.8	13
83	Clinical applications of molecular genetic testing in hematologic malignancies: Advantages and limitations. <i>Human Pathology</i> , 2003, 34, 352-358.	2.0	11
84	Recent insights into the biology of Hodgkin lymphoma: unraveling the mysteries of the Reed-Sternberg cell. <i>Expert Review of Molecular Diagnostics</i> , 2007, 7, 805-820.	3.1	11
85	Isolated Bowel Relapse in Acute Promyelocytic Leukemia: An Unusual Site of Extramedullary Recurrence. <i>Journal of Clinical Oncology</i> , 2010, 28, e550-e553.	1.6	11
86	The cytological features of CAR(T) cells. <i>British Journal of Haematology</i> , 2016, 175, 366-366.	2.5	11
87	Targeted massively parallel sequencing of mature lymphoid neoplasms: assessment of empirical application and diagnostic utility in routine clinical practice. <i>Modern Pathology</i> , 2021, 34, 904-921.	5.5	11
88	Development of rheumatoid arthritis after treatment of large granular lymphocyte leukemia with deoxycoformycin. , 1998, 57, 253-257.		10
89	Lineage Ambiguity, Infidelity, and Promiscuity in Immunophenotypically Complex Acute Leukemias. <i>American Journal of Clinical Pathology</i> , 2007, 128, 545-548.	0.7	10
90	Therapy-associated Lymphoid Proliferations. <i>Advances in Anatomic Pathology</i> , 2011, 18, 199-205.	4.3	10

#	ARTICLE	IF	CITATIONS
91	Molecular-Based Classification of Acute Myeloid Leukemia and Its Role in Directing Rational Therapy. <i>Molecular Diagnosis and Therapy</i> , 2012, 16, 357-369.	3.8	10
92	A Modified Integrated Genetic Model for Risk Prediction in Younger Patients with Acute Myeloid Leukemia. <i>PLoS ONE</i> , 2016, 11, e0153016.	2.5	10
93	Transcriptome and unique cytokine microenvironment of Castleman disease. <i>Modern Pathology</i> , 2022, 35, 451-461.	5.5	10
94	Evidence of myeloid differentiation in non-M3 acute myeloid leukemia treated with the retinoid X receptor agonist bexarotene. <i>Cancer Biology and Therapy</i> , 2007, 6, 18-21.	3.4	9
95	Minimal residual disease testing to predict relapse following transplant for AML and high-grade myelodysplastic syndromes. <i>Expert Review of Molecular Diagnostics</i> , 2011, 11, 361-366.	3.1	9
96	Microsphere-Based Multiplex Analysis of DNA Methylation in Acute Myeloid Leukemia. <i>Journal of Molecular Diagnostics</i> , 2014, 16, 207-215.	2.8	9
97	<i>BRAF</i> kinase domain mutations in <i>de novo</i> acute myeloid leukemia with monocytic differentiation. <i>Leukemia and Lymphoma</i> , 2017, 58, 743-745.	1.3	9
98	Chronic myeloid neoplasms harboring concomitant mutations in myeloproliferative neoplasm driver genes (JAK2/MPL/CALR) and SF3B1. <i>Modern Pathology</i> , 2021, 34, 20-31.	5.5	9
99	Ionized Calcium Binding Adaptor Molecule 1 (IBA1). <i>American Journal of Clinical Pathology</i> , 2021, 156, 86-99.	0.7	9
100	Laboratory Workup of Lymphoma in Adults. <i>American Journal of Clinical Pathology</i> , 2021, 155, 12-37.	0.7	9
101	Leukemia Stem Cells Are Characterized By CLEC12A Expression and Chemotherapy Refractoriness That Can be Overcome By Targeting with Chimeric Antigen Receptor T Cells. <i>Blood</i> , 2016, 128, 766-766.	1.4	9
102	Laboratory Workup of Lymphoma in Adults: Guideline From the American Society for Clinical Pathology and the College of American Pathologists. <i>Archives of Pathology and Laboratory Medicine</i> , 2021, 145, 269-290.	2.5	9
103	Myelodysplastic/myeloproliferative neoplasms-unclassifiable with isolated isochromosome 17q represents a distinct clinico-biologic subset: a multi-institutional collaborative study from the Bone Marrow Pathology Group. <i>Modern Pathology</i> , 2021, , .	5.5	9
104	Crystal-storing histiocytosis in plasma cell myeloma. <i>American Journal of Hematology</i> , 2010, 85, 444-445.	4.1	8
105	Transmission of an expanding donor-derived del(20q) clone through allogeneic hematopoietic stem cell transplantation without the development of a hematologic neoplasm. <i>Cancer Genetics</i> , 2015, 208, 625-629.	0.4	8
106	Falsely Increased Plasma Lactate Dehydrogenase without Hemolysis Following Transport through Pneumatic Tube System. <i>Journal of Applied Laboratory Medicine</i> , The, 2019, 4, 433-438.	1.3	8
107	Clinical, immunophenotypic and genomic findings of NK lymphoblastic leukemia: a study from the Bone Marrow Pathology Group. <i>Modern Pathology</i> , 2021, 34, 1358-1366.	5.5	8
108	¹⁸ F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Following Chimeric Antigen Receptor T-cell Therapy in Large B-cell Lymphoma. <i>Molecular Imaging and Biology</i> , 2021, 23, 818-826.	2.6	8

#	ARTICLE	IF	CITATIONS
109	Commentary Minimal Residual Disease: How Low Do We Go?. <i>Molecular Diagnosis and Therapy</i> , 2001, 6, 155-160.	1.1	8
110	The Basis and Rational Use of Molecular Genetic Testing in Mature B-cell Lymphomas. <i>Advances in Anatomic Pathology</i> , 2010, 17, 333-358.	4.3	7
111	Mutations in myelodysplastic syndromes: Core abnormalities and CHIPping away at the edges. <i>International Journal of Laboratory Hematology</i> , 2020, 42, 671-684.	1.3	7
112	VEXAS: a vivid new syndrome associated with vacuoles in various hematopoietic cells. <i>Blood</i> , 2021, 137, 3690-3690.	1.4	7
113	Development and implementation of a custom integrated database with dashboards to assist with hematopathology specimen triage and traffic. <i>Journal of Pathology Informatics</i> , 2014, 5, 29.	1.7	7
114	Large B-Cell Lymphoma Masquerading As Acute Leukemia. <i>Journal of Clinical Oncology</i> , 2006, 24, 1950-1951.	1.6	6
115	Hereditary elliptocytosis. <i>Blood</i> , 2013, 121, 3066-3066.	1.4	6
116	NPM1 for MRD? Droplet Like It's Hot!. <i>Journal of Molecular Diagnostics</i> , 2017, 19, 498-501.	2.8	6
117	Most Myeloid Neoplasms With Deletion of Chromosome 16q Are Distinct From Acute Myeloid Leukemia With Inv(16)(p13.1q22). <i>American Journal of Clinical Pathology</i> , 2017, 147, 411-419.	0.7	6
118	Conjunctival Pediatric-Type Follicular Lymphoma. <i>Ophthalmic Plastic and Reconstructive Surgery</i> , 2020, 36, e46-e49.	0.8	6
119	Acute promyelocytic leukemia presenting as a paraspinal mass. <i>Journal of Community and Supportive Oncology</i> , 2016, 14, 126-129.	0.1	6
120	An Alternative SplicedRNASELVariant in Peripheral Blood Leukocytes. <i>Journal of Interferon and Cytokine Research</i> , 2006, 26, 820-826.	1.2	5
121	Multifocal Mantle Cell Lymphoma In Situ in the Setting of a Composite Lymphoma. <i>American Journal of Clinical Pathology</i> , 2015, 143, 274-282.	0.7	5
122	Hodgkin lymphoma patients have an increased incidence of idiopathic acquired aplastic anemia. <i>PLoS ONE</i> , 2019, 14, e0215021.	2.5	5
123	Clinical syndromes of transformation in clonal hematologic disorders. <i>American Journal of Medicine</i> , 2001, 111, 480-488.	1.5	4
124	Ig γ 2(CD79b)mRNA expression in chronic lymphocytic leukaemia cells correlates with immunoglobulin heavy chain gene mutational status but does not serve as an independent predictor of clinical severity. <i>American Journal of Hematology</i> , 2007, 82, 712-720.	4.1	4
125	Transient Blood Transfusion Reaction Masquerading As a Post-Transplantation Lymphoproliferative Disorder Mimicking Acute Leukemia Cutis. <i>Journal of Clinical Oncology</i> , 2011, 29, e751-e753.	1.6	4
126	Genetics of Diffuse Large B-Cell Lymphoma. <i>Cancer Journal (Sudbury, Mass)</i> , 2014, 20, 43-47.	2.0	4

#	ARTICLE	IF	CITATIONS
127	Pediatric chronic myeloid leukemia with inv(3)(q21q26.2) and T lymphoblastic transformation: a case report. <i>Biomarker Research</i> , 2016, 4, 14.	6.8	4
128	Genetic studies in the evaluation of myeloproliferative neoplasms. <i>Seminars in Hematology</i> , 2019, 56, 7-14.	3.4	4
129	High-throughput sequencing of the T-cell receptor β chain gene distinguishes 2 subgroups of cutaneous T-cell lymphoma. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 1148-1150.e1.	1.2	4
130	Orbital and Ocular Adnexal Manifestations of Adult T-Cell Leukemia/Lymphoma: a Case Report and Systematic Review. <i>Ophthalmic Plastic and Reconstructive Surgery</i> , 2021, 37, 201-211.	0.8	4
131	A Phase I Clinical Trial Using Eltrombopag in Patients with Acute Myelogenous Leukemia. <i>Blood</i> , 2012, 120, 3576-3576.	1.4	4
132	An extremely indolent T-cell leukemia: an 18-year follow-up. <i>Journal of Community and Supportive Oncology</i> , 2016, 14, 76-78.	0.1	4
133	Molecular diagnosis in lymphoma. <i>Psychophysiology</i> , 2005, 4, 313-23.	1.1	4
134	Unusual Hematologic Malignancies. <i>Journal of Clinical Oncology</i> , 2002, 20, 3737-3739.	1.6	3
135	Molecular diagnosis in lymphoma. <i>Current Oncology Reports</i> , 2004, 6, 369-379.	4.0	3
136	Molecular Malfeasance Mediating Myeloid Malignancies: The Genetics of Acute Myeloid Leukemia. <i>Methods in Molecular Biology</i> , 2017, 1633, 1-17.	0.9	3
137	A reevaluation of erythroid predominance in Acute Myeloid Leukemia using the updated WHO 2016 Criteria. <i>Modern Pathology</i> , 2018, 31, 873-880.	5.5	3
138	Next-Generation Sequencing for Lymphomas. <i>Journal of Molecular Diagnostics</i> , 2018, 20, 163-165.	2.8	3
139	A 2020 Vision Into Hodgkin Lymphoma Biology. <i>Advances in Anatomic Pathology</i> , 2020, 27, 269-277.	4.3	3
140	Aplastic anemia in a patient with COVID due to NFKB1 haploinsufficiency. <i>Journal of Physical Education and Sports Management</i> , 2020, 6, a005769.	1.2	3
141	Rapid fluorescence <i>in situ</i> hybridisation optimises induction therapy for acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2020, 191, 935-938.	2.5	3
142	Transitioning T-Cell Clonality Testing to High-Throughput Sequencing. <i>Journal of Molecular Diagnostics</i> , 2021, 23, 781-783.	2.8	3
143	Limited FISH Testing for MDS-Defining Cytogenetic Abnormalities Rapidly Identifies Patients with Newly Diagnosed AML Eligible for CPX-351. <i>Blood</i> , 2018, 132, 4785-4785.	1.4	3
144	Successful treatment of angioimmunoblastic T-cell lymphoma with the retinoid X receptor agonist, bexarotene. <i>Leukemia and Lymphoma</i> , 2011, 52, 1815-1817.	1.3	2

#	ARTICLE	IF	CITATIONS
145	Molecular Diagnostics of Acute Myeloid Leukemia. <i>Journal of Molecular Diagnostics</i> , 2013, 15, 27-30.	2.8	2
146	Myeloid neoplasm with eosinophilia and <i>PCM1-JAK2</i> associated with acute promyelocytic leukemia with <i>PML-RARA</i> . <i>Leukemia and Lymphoma</i> , 2019, 60, 2299-2303.	1.3	2
147	Leukemic lineage switch in a t(8;22)(p11.2;q11.2)/BCR-FGFR1-rearranged myeloid/lymphoid neoplasm with RUNX1 mutation – diagnostic pitfalls and clinical management including FGFR1 inhibitor pemigatinib. <i>Leukemia and Lymphoma</i> , 2020, 61, 450-454.	1.3	2
148	Classic Hodgkin Lymphoma – Old Disease, New Directions: An Update on Pathology, Molecular Features and Biological Prognostic Markers. <i>Acta Medica Academica</i> , 2021, 50, 110.	0.8	2
149	Interpretative differences of combined cytogenetic and molecular profiling highlights differences between MRC and ELN classifications of AML. <i>Cancer Genetics</i> , 2021, 256-257, 68-76.	0.4	2
150	Leukemia Cutis With Histopathologic and Immunophenotypic Features Resembling S100-Negative CD1a-Positive Cutaneous Histiocytosis. <i>American Journal of Dermatopathology</i> , 2021, 43, 574-575.	0.6	2
151	Characterizing Mortality Associated with Idiopathic Multicentric Castleman Disease. <i>Blood</i> , 2021, 138, 1623-1623.	1.4	2
152	The disease course of Castleman disease patients with fatal outcomes in the <i>ACCELERATE</i> registry. <i>British Journal of Haematology</i> , 2022, . .	2.5	2
153	Molecular genetic biomarkers in hematological malignancies. <i>Journal of Cellular Biochemistry</i> , 1996, 63, 165-171.	2.6	1
154	T Cell Receptor β -Chain Gene Polymerase Chain Reaction to Diagnose Central Nervous System Involvement by Cutaneous T Cell Lymphoma. <i>Journal of Molecular Diagnostics</i> , 2002, 4, 118-120.	2.8	1
155	Reactive versus neoplastic lymphoid follicles: proliferation and death versus quiescence and staying alive. <i>British Journal of Haematology</i> , 2004, 126, 757-757.	2.5	1
156	Extracavitary primary effusion lymphoma in an HIV-positive patient with Kaposi sarcoma-associated. <i>Community Oncology</i> , 2009, 6, 523-525.	0.2	1
157	Isolated Langerhans Cell Histiocytosis of the Lacrimal Gland in Conjunction With Mucosa-Associated Lymphoid Tissue Lymphoma and Elevated IgG4 Plasma Cells. <i>Ophthalmic Plastic and Reconstructive Surgery</i> , 2019, 35, e92-e94.	0.8	1
158	FBXW7 mutations in acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2019, 60, 1601-1602.	1.3	1
159	Next-generation sequencing to identify mutations that may predict outcome after allogeneic stem cell transplantation for AML. <i>Journal of Clinical Oncology</i> , 2014, 32, 7043-7043.	1.6	1
160	Mutational Analysis Reinforces the Diagnosis of Nodal Marginal Zone Lymphoma With Robust PD1-positive T-Cell Hyperplasia. <i>American Journal of Surgical Pathology</i> , 2021, 45, 143-145.	3.7	1
161	Performance Evaluation Study of a Novel Digital Microscopy System for the Quantitative Analysis of Bone Marrow Aspirates. <i>Blood</i> , 2021, 138, 4000-4000.	1.4	1
162	Germline <i>POT1</i> Variants Can Predispose to a Variety of Hematologic Neoplasms. <i>Blood</i> , 2020, 136, 2-4.	1.4	1

#	ARTICLE	IF	CITATIONS
163	Toward a Therapeutically Relevant, Molecularly Based Classification of Lymphoma. American Journal of Clinical Pathology, 2007, 127, 12-14.	0.7	0
164	Diagnostic challenges in the myelodysplastic syndromes: the current and future role of genetic and immunophenotypic studies. Expert Opinion on Medical Diagnostics, 2009, 3, 275-291.	1.6	0
165	Making a Meal of Multiple Mutations in Acute Myeloid Malignancies. Journal of Molecular Diagnostics, 2011, 13, 605-608.	2.8	0
166	Development of an Integrated Database and Dashboard for Bone Marrow Specimen Triage. American Journal of Clinical Pathology, 2013, 140, A067-A067.	0.7	0
167	Chronic lymphocytic leukemia with a t(8;14)(q24;q32): <sc>FISH</sc>ing catches a (sheepish) red herring. American Journal of Hematology, 2015, 90, 1187-1188.	4.1	0
168	B-cells behaving badly II: A better basis to behold belligerence in aggressive B-cell lymphomas. Pathology, 2016, 48, S9.	0.6	0
169	Longitudinal targeted next-generation sequencing in a patient with acute myeloid leukaemia. British Journal of Haematology, 2019, 186, 801-801.	2.5	0
170	Expedited Analysis and Reporting of Multiple Mutations that Modify Medical Management of Myeloid Malignancies. Journal of Molecular Diagnostics, 2019, 21, 13-15.	2.8	0
171	An atypical systemic form of chronic active EBV infection. Leukemia and Lymphoma, 2020, 61, 3030-3032.	1.3	0
172	Anemia in a young Guinean male. Clinical Case Reports (discontinued), 2021, 9, e04593.	0.5	0
173	Philadelphia Chromosome (Ph ⁺) Negative, MLL-Rearranged AML Arising in a Patient Treated with Imatinib for CML. Blood, 2005, 106, 4880-4880.	1.4	0
174	A Phase I Trial of Bexarotene, a Retinoid X Receptor Agonist, in non-M3 Acute Myeloid Leukemia: Evidence of Myeloid Differentiation and Clinical Activity. Blood, 2006, 108, 1955-1955.	1.4	0
175	A Phase II Trial of Bexarotene, a Retinoid X Receptor Agonist, in Non-M3 Acute Myeloid Leukemia. Blood, 2008, 112, 4040-4040.	1.4	0
176	A Robust Xenotransplantation Model for Acute Myeloid Leukemia. Blood, 2008, 112, 2939-2939.	1.4	0
177	Diverse Histopathologic and Molecular Responses of Acute Myeloid Leukemia to the FLT3 Inhibitor Quizartinib (AC220). Blood, 2012, 120, 885-885.	1.4	0
178	Clinicopathologic Characterization of Acute Myeloid Leukemia and Myelodysplastic Syndrome with Inv(3)(q21q26.2)/t(3;3)(q21;q26.2) Reveals That Complex Karyotype but Not Blast Percentage Is Associated with Poor Survival; A Bone Marrow Pathology Group Study. Blood, 2012, 120, 3847-3847.	1.4	0
179	Predicting prognosis in patients with acute myeloid leukemia: The role of next-generation sequencing and mutational profiling. Journal of Clinical Oncology, 2014, 32, 7068-7068.	1.6	0
180	Next Generation Mutational Profiling Improves Prognostication in Younger Patients with Acute Myeloid Leukemia. Blood, 2014, 124, 1032-1032.	1.4	0

#	ARTICLE	IF	CITATIONS
181	Mutational Shift in FLT3 and NPM1-Positive Acute Myeloid Leukemia (AML) Relative to Therapy and Disease Progression. <i>Blood</i> , 2016, 128, 2866-2866.	1.4	0
182	Classical Hodgkin Lymphoma Patients Have an Increased Incidence of Idiopathic Acquired Aplastic Anemia. <i>Blood</i> , 2018, 132, 5098-5098.	1.4	0
183	Clinical, Immunophenotypic and Genomic Findings of Acute Undifferentiated Leukemia and Comparison to AML with Minimal Differentiation: A Study from the Bone Marrow Pathology Group. <i>Blood</i> , 2018, 132, 1491-1491.	1.4	0
184	Characterization of Castleman Disease Reveals Patients with Oligocentric Adenopathy and Clinicopathologic Characteristics Similar to Unicentric Castleman Disease. <i>Blood</i> , 2021, 138, 1622-1622.	1.4	0
185	Clinical laboratory mutation analysis performed on aggressive B cell non-Hodgkin lymphoma patient biopsies.. <i>Journal of Clinical Oncology</i> , 2022, 40, e19561-e19561.	1.6	0